Upload Avatar (500 x 500)
Yufeng Zhou
zyf@scau.edu.cn
English, Chinese
Guangdong
South China Agricultural University
Veterinary Medicine
  • 2017.08-2018.08 Joint PhD: University of California, Los Angeles (UCLA)
  • 2013.09-2018.12 PhD in Basic Veterinary Medicine: South China Agricultural University
  • 2009.09-2013.06 Bachelor's in Veterinary Medicine: South China Agricultural University
  • Published over 30 papers in international and domestic academic journals
  • First or corresponding author of 15 SCI-indexed papers
  • Recipient of ChiCAST Honorary Contribution Individual Award
  • 2019.01-present - South China Agricultural University - Associate Professor
  • ChiCAST Honorary Contribution Individual Award
Veterinary Pharmacokinetics
Pharmacokinetic/Pharmacodynamic Modeling
Antimicrobial Susceptibility Breakpoints
Bacterial Resistance Control Strategies
  • Pharmacodynamic Target Assessment and PK/PD Cutoff Determination for Gamithromycin Against Streptococcus suis in Piglets, Wang RL, Liu P, Chen XF, Yao X, Liao XP, Liu YH, Sun J, Zhou YF, 2022
  • Comparison of PK/PD Targets and Cutoff Values for Danofloxacin Against Pasteurella multocida and Haemophilus parasuis in Piglets, Zhou YF, Sun Z, Wang RL, Li JG, Niu CY, Li XA, Feng YY, Sun J, Liu YH, Liao XP, 2022
  • Activity of Tigecycline or Colistin in Combination with Zidovudine against Escherichia coli Harboring tet(X) and mcr-1, Zhou YF, Liu P, Dai SH, Sun J, Liu YH, Liao XP, 2021
  • In Vivo Pharmacodynamic Target Assessment of Antofloxacin against Streptococcus pneumoniae and Staphylococcus aureus in a Neutropenic Murine Pneumonia Model, Zhou YF, Liu P, Dai SH, Sun J, Liu YH, Liao XP, 2020
  • Linezolid and Rifampicin Combination to Combat cfr-Positive Multidrug-Resistant MRSA in Murine Models of Bacteremia and Skin and Skin Structure Infection, Zhou YF, Li L, Tao MT, Sun J, Liao XP, Liu YH, Xiong YQ, 2020
  • Colistin Combined With Tigecycline: A Promising Alternative Strategy to Combat Escherichia coli Harboring bla NDM-5 and mcr-1, Zhou YF, Liu P, Zhang CJ, Liao XP, Sun J, Liu YH, 2020
  • Epidemiological and PK/PD cutoff values determination and PK/PD-based dose assessment of gamithromycin against Haemophilus parasuis in piglets, Zhou YF, Bu MX, Liu P, Sun J, Liu YH, Liao XP, 2020
  • Increased activity of linezolid in combination with rifampicin in a murine pneumonia model due to MRSA, Zhou YF, Xiong YQ, Tao MT, Li L, Bu MX, Sun J, Liao XP, Liu YH, 2018
  • In vivo bioluminescent monitoring of therapeutic efficacy and pharmacodynamic target assessment of antofloxacin against Escherichia coli in a neutropenic murine thigh infection model, Zhou YF, Tao MT, He YZ, Sun J, Liu YH, Liao XP, 2018
  • Increased activity of colistin in combination with amikacin against Escherichia coli co-producing NDM-5 and MCR-1, Zhou YF, Tao MT, Feng Y, Yang RS, Liao XP, Liu YH, Sun J, 2017
  • In vivo pharmacokinetic and pharmacodynamic profiles of antofloxacin against Klebsiella pneumoniae in a neutropenic murine lung infection model, Zhou YF, Tao MT, Huo W, Liao XP, Sun J, Liu YH, 2017
  • Pharmacodynamic evaluation and PK/PD-based dose prediction of tulathromycin: a potential new indication for Streptococcus suis infection, Zhou YF, Peng HM, Bu MX, Liu YH, Sun J, Liao XP, 2017
  • Pharmacokinetic/ pharmacodynamic correlation of cefquinome against experimental catheter-associated biofilm infection due to Staphylococcus aureus, Zhou YF, Shi W, Yu Y, Tao MT, Xiong YQ, Sun J, Liu YH, 2016
  • Ex vivo pharmacokinetic/pharmacodynamic relationship of valnemulin against Clostridium perfringens in plasma, the small intestinal and caecal contents of rabbits, Zhou YF, Yu Y, Sun J, Tao MT, Zhou WJ, Li X, Liao XP, Liu YH, 2016
  • Pharmacokinetics, bioavailability and PK/PD relationship of cefquinome for Escherichia coli in Beagle dogs, Zhou YF, Zhao DH, Yu Y, Yang X, Shi W, Peng YB, Liu YH, 2015
Veterinary Pharmacokinetics Pharmacodynamics Modeling Antimicrobial Susceptibility Breakpoints Bacterial Resistance Control

Contact us

Let's talk!
* Required
* Required
* Required
* Invalid email address
By submitting this form, you agree that IoT ONE may contact you with insights and marketing messaging.
No thanks, I don't want to receive any marketing emails from IoT ONE.
Submit

Thank you for your message!
We will contact you soon.